盐酸埃克替尼治疗EGFR敏感突变非小细胞肺癌脑转移患者的疗效观察

The efficacy of single-agenticotinib hydrochloride in patients with advanced EGFR-mutated non-small cell lung cancer

目的探索盐酸埃克替尼单药治疗晚期EGFR突变非小细胞肺癌合并多发脑转移患者的疗效。方法选取我院门诊2013年7月至2017年6月期间收治的非小细胞肺癌脑转移患者22例,回顾性分析其接受盐酸埃克替尼单药口服的疗效。结果 22例非小细胞肺癌脑转移患者接受盐酸埃克替尼单药的总体中位无进展生存期(progression-free survival,PFS)为13.0个月(95%CI11.87～14.13),肿瘤缓解率(objective response rate,ORR)和疾病控制率(disease control rate,DCR)分别为40.9%和100%。根据性别、吸烟史、脑转移症状、EGFR突变亚型、既往治疗情况对所有患者进行PFS和ORR的分析结果显示,以上临床特征对脑转移患者的PFS和ORR无显著影响。结论盐酸埃克替尼单药治疗晚期EGFR突变肺腺癌脑转移具有较好的疗效。

Objective To investigate the efficacy of single-agenticotinib hydrochloride in patients with advanced EGFR-mutated non-small cell lung cancer（ NSCLC） with brain metastases. Methods Twenty-two NSCLC patients with brain metastases from NSCLC admitted in our department from July 2013 to June 2017 were enrolled in this study. Retrospective analysis was conducted to evaluate the efficacy of oral icotinib in these patients. Results The overall median progression-free survival（ PFS） was 13. 0 months（ 95% CI11. 87 ～ 14. 13）,and the objective response rate（ ORR） and disease control rate（ DCR） were 40. 9% and 100%,respectively. Subgroup analysis of PFS and ORR was conducted according to sex,smoking status,EGFR subtypes,and presence of previous treatment,showing no significant difference of PFS and ORR in these groups. Conclusion Single-agent icotinib showed favorable efficacy as treatment for EGFR-mutated NSCLC with brain metastases.